Targeted Therapy in Biliary Tract Cancers

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A paradigm shift towards molecular-based, personalized cancer therapeutics has occurred in recent years and a number of targeted drugs have emerged. Various targeted therapies like erlotinib, trastuzumab, and cetuximab have been approved in lung, breast, and colon cancers, respectively. Numerous clinical trials involving targeted drugs in biliary tract cancers are currently in progress, though none have been approved for this disease. Biliary tract cancers are divided into separate entities both anatomically and in terms of pathogenesis but are grouped together in most trials given their rarity. Combination chemotherapy involving cisplatin and gemcitabine is the current standard of care in the metastatic setting. In this review, we will discuss the various molecular pathways implicated in biliary tract cancers and potential therapeutic targets.

Original languageEnglish (US)
Article number48
JournalCurrent Treatment Options in Oncology
Volume16
Issue number10
DOIs
StatePublished - Oct 17 2015

Fingerprint

Biliary Tract Neoplasms
gemcitabine
Standard of Care
Combination Drug Therapy
Pharmaceutical Preparations
Colonic Neoplasms
Cisplatin
Lung Neoplasms
Therapeutics
Clinical Trials
Breast Neoplasms
Neoplasms

Keywords

  • Biliary tract cancer
  • EGFR
  • Targeted therapy
  • Trial
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Targeted Therapy in Biliary Tract Cancers. / Merla, Amartej; Liu, Kenneth G.; Rajdev, Lakshmi.

In: Current Treatment Options in Oncology, Vol. 16, No. 10, 48, 17.10.2015.

Research output: Contribution to journalArticle

@article{7fe494a209a94674a8a9b0a11c905d67,
title = "Targeted Therapy in Biliary Tract Cancers",
abstract = "A paradigm shift towards molecular-based, personalized cancer therapeutics has occurred in recent years and a number of targeted drugs have emerged. Various targeted therapies like erlotinib, trastuzumab, and cetuximab have been approved in lung, breast, and colon cancers, respectively. Numerous clinical trials involving targeted drugs in biliary tract cancers are currently in progress, though none have been approved for this disease. Biliary tract cancers are divided into separate entities both anatomically and in terms of pathogenesis but are grouped together in most trials given their rarity. Combination chemotherapy involving cisplatin and gemcitabine is the current standard of care in the metastatic setting. In this review, we will discuss the various molecular pathways implicated in biliary tract cancers and potential therapeutic targets.",
keywords = "Biliary tract cancer, EGFR, Targeted therapy, Trial, VEGF",
author = "Amartej Merla and Liu, {Kenneth G.} and Lakshmi Rajdev",
year = "2015",
month = "10",
day = "17",
doi = "10.1007/s11864-015-0366-0",
language = "English (US)",
volume = "16",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Targeted Therapy in Biliary Tract Cancers

AU - Merla, Amartej

AU - Liu, Kenneth G.

AU - Rajdev, Lakshmi

PY - 2015/10/17

Y1 - 2015/10/17

N2 - A paradigm shift towards molecular-based, personalized cancer therapeutics has occurred in recent years and a number of targeted drugs have emerged. Various targeted therapies like erlotinib, trastuzumab, and cetuximab have been approved in lung, breast, and colon cancers, respectively. Numerous clinical trials involving targeted drugs in biliary tract cancers are currently in progress, though none have been approved for this disease. Biliary tract cancers are divided into separate entities both anatomically and in terms of pathogenesis but are grouped together in most trials given their rarity. Combination chemotherapy involving cisplatin and gemcitabine is the current standard of care in the metastatic setting. In this review, we will discuss the various molecular pathways implicated in biliary tract cancers and potential therapeutic targets.

AB - A paradigm shift towards molecular-based, personalized cancer therapeutics has occurred in recent years and a number of targeted drugs have emerged. Various targeted therapies like erlotinib, trastuzumab, and cetuximab have been approved in lung, breast, and colon cancers, respectively. Numerous clinical trials involving targeted drugs in biliary tract cancers are currently in progress, though none have been approved for this disease. Biliary tract cancers are divided into separate entities both anatomically and in terms of pathogenesis but are grouped together in most trials given their rarity. Combination chemotherapy involving cisplatin and gemcitabine is the current standard of care in the metastatic setting. In this review, we will discuss the various molecular pathways implicated in biliary tract cancers and potential therapeutic targets.

KW - Biliary tract cancer

KW - EGFR

KW - Targeted therapy

KW - Trial

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84939219427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939219427&partnerID=8YFLogxK

U2 - 10.1007/s11864-015-0366-0

DO - 10.1007/s11864-015-0366-0

M3 - Article

C2 - 26266637

AN - SCOPUS:84939219427

VL - 16

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 10

M1 - 48

ER -